Cited 4 times in
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2022-12-22T02:01:32Z | - |
dc.date.available | 2022-12-22T02:01:32Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191425 | - |
dc.description.abstract | Background A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma. Methods The KCSG-ST19-16 study enrolled a total of 1063 patients from 56 hospitals in South Korea with advanced gastric or GEJ adenocarcinoma, who had received second-line treatment with ramucirumab plus paclitaxel. HER2 status was known for 994 (93.5%) of these patients, who were thus included in the subgroup analysis. Results In total, 163 of 994 patients (16.4%), had HER2-positive gastric or GEJ adenocarcinoma. The objective response rate to ramucirumab plus paclitaxel treatment was significantly higher in patients with HER2-positive disease compared to those with HER2-negative disease (23.0% [95% confidence interval (CI), 15.9-30.1] vs. 15.1% [95% CI, 12.3-17.9], p = 0.025). The median progression-free survival was longer in patients with HER2-positive versus HER2-negative disease, but the difference was not statistically significant (4.3 months [95% CI, 3.7-5.3] vs 3.7 months [95% CI, 3.4-4.0], p = 0.054). There was no statistically significant difference in median overall survival (OS) between the groups (9.8 months [95% CI, 8.9-12.3] vs 10.1 months [95% CI, 9.2-10.9], p = 0.564). Conclusions In patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease. However, an increased response to treatment was not associated with an improvement in OS. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer-Verlag Tokyo | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adenocarcinoma* / pathology | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Esophageal Neoplasms | - |
dc.subject.MESH | Esophagogastric Junction / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Paclitaxel / therapeutic use | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Stomach Neoplasms* / pathology | - |
dc.title | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Bum Jun Kim | - |
dc.contributor.googleauthor | Hee-Jung Jee | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Hye Sook Han | - |
dc.contributor.googleauthor | Min-Hee Ryu | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.contributor.googleauthor | Jong Gwang Kim | - |
dc.contributor.googleauthor | Woo Kyun Bae | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Ji-Hye Byun | - |
dc.contributor.googleauthor | Dong Sook Kim | - |
dc.contributor.googleauthor | Young Ju Suh | - |
dc.contributor.googleauthor | Hyonggin An | - |
dc.contributor.googleauthor | Dae Young Zang | - |
dc.identifier.doi | 10.1007/s10120-021-01276-4 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00916 | - |
dc.identifier.eissn | 1436-3305 | - |
dc.identifier.pmid | 35015188 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s10120-021-01276-4 | - |
dc.subject.keyword | ErbB-2 | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | Ramucirumab | - |
dc.subject.keyword | Stomach neoplasms | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 609 | - |
dc.citation.endPage | 618 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, Vol.25(3) : 609-618, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.